Pharma Journalist -

Ipsen and Day One Biopharmaceuticals (Day One), announced a new global partnership outside the U.S. for tovorafenib, an oral, once-weekly, type II RAF inhibitor for pediatric low grade…
Read More...

Astellas Pharma Inc. and Graduate School of Medicine / Faculty of Medicine, Osaka University announced that Astellas Institute for Regenerative Medicine (a wholly owned subsidiary of…
Read More...

The Phase III ARANOTE trial, investigating NUBEQA (darolutamide) plus androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC),…
Read More...

Rona Therapeutics, a clinical stage pioneering platform company in nucleic acid drug research and development, announced the completion of $35 Million Series A+ financing. This round…
Read More...

CatalYm announced the completion of a $150 million Series D financing. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s…
Read More...

Merck, a leading science and technology company, announced the start of commercial production of its first GMP (Good Manufacturing Practices) compliant manufacturing line for cell…
Read More...

Mabwell, an innovation-driven biopharmaceutical company with entire industry chain, announced that its self-developed novel B7-H3-targeting ADC has been granted Orphan Drug Designation…
Read More...

AstraZeneca announced the successful completion of the acquisition of Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine…
Read More...

Evotec SE announced it has entered into a multi-year master research collaboration and option and license agreement with Pfizer. Under the agreement, Evotec and Pfizer will initially…
Read More...

Johnson & Johnson announced that it has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics to secure the global rights to NM26, a …
Read More...